To evaluate the clinical benefits and risks associated with whole-body MRI screening in the general population, emphasizing the lack of supporting evidence.
Key Findings:
Whole-body MRI identifies cancer in 1 to 2 out of 100 people screened, with many detected cancers being low risk or already advanced.
No evidence shows that screening improves quality of life or survival.
Interpretation:
The authors argue that patients may not be fully informed about the limitations and potential harms of whole-body MRI screening, particularly in commercial settings.
Limitations:
Current evidence does not support the clinical utility of whole-body MRI in the general population, and no major medical society recommends its use due to low likelihood of identifying treatable disease.
Conclusion:
While whole-body MRI may have future potential in selected populations, current commercial practices lack sufficient evidence for widespread use, highlighting the need for rigorous evaluation.
